MANILA, July 17 — A growing body of cost-effectiveness research from the United States is showing that a specific genomic test for breast cancer not only spares patients from unnecessary chemotherapy but also delivers significant savings across the healthcare system. The test, known as Oncotype DX, is designed for patients with node-negative, hormone receptor-positive breast cancer. It analyzes the activity of a group of genes within a tumor to predict the likelihood of recurrence, helping doctors and patients decide whether chemotherapy would actually be beneficial.
A 2013 study published in the Journal of Clinical Oncology estimated that routine use of Oncotype DX in this patient group saved approximately $40 million annually in direct medical costs across the United States, primarily by avoiding chemotherapy that would not have helped. The test itself costs about $4,000 per patient, but the study found that the savings from avoiding chemotherapy — including drug costs, administration, and management of side effects — far outweigh this expense.
For families across the region, the implications are clear: fewer patients enduring the harsh side effects of treatments that offer little benefit.
Cost-effectiveness confirmed by multiple studies
A 2015 analysis in Breast Cancer Research and Treatment reported that Oncotype DX testing was cost-effective, with an incremental cost-effectiveness ratio of less than $50,000 per quality-adjusted life year gained. This figure is a standard benchmark used by health economists to determine whether a medical intervention provides good value for money. The test has been covered by Medicare since 2006 and is also covered by most private insurers, including UnitedHealthcare and Aetna.
The Centers for Medicare & Medicaid Services has included Oncotype DX in its coverage for breast cancer patients meeting specific criteria. The economic impact extends beyond direct medical costs.
Patients who avoid chemotherapy experience fewer workdays lost and lower out-of-pocket expenses. A 2018 study in the Journal of Medical Economics found that Oncotype DX testing reduced overall healthcare spending by $2,000 to $3,000 per patient over five years.
Driven by value-based care
The test’s adoption has been driven by value-based care models, as it aligns with the goal of reducing unnecessary treatment. This approach is gaining traction in healthcare systems worldwide, including in parts of Asia where healthcare budgets are under increasing pressure. Closer to home, the question for health systems in the Philippines and across Southeast Asia is whether such genomic testing can be made accessible and affordable for local populations.
While the studies cited are from a US healthcare perspective, the underlying principle — that a targeted, upfront investment in testing can prevent far greater costs down the line — is one that resonates with policymakers looking to stretch limited resources. What to watch next: As more countries in the region develop their own health technology assessment frameworks, the cost-effectiveness data from these US studies could inform coverage decisions for genomic testing in breast cancer care.
The challenge will be balancing the upfront cost of the test against the long-term savings and improved quality of life for patients.
Sources
{“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “Oncotype DX Testing Cost-Effectiveness Analyzed in US Healthcare”, “description”: “MANILA, July 17 — A growing body of cost-effectiveness research from the United States is showing that a specific genomic test for breast cancer not…”, “datePublished”: “2026-07-17T09:30:00+00:00”, “author”: {“@type”: “Person”, “name”: “Merry Gel Sigui”}, “publisher”: {“@type”: “Organization”, “name”: “InfoPulse Today”, “url”: “https://newsfeed.infopulsetoday.com/”}, “citation”: [{“@type”: “CreativeWork”, “url”: “https://en.wikipedia.org/wiki/Cost-effectiveness_analysis”}]}
